SEC Company Response from Anixa Biosciences Inc (ANIX) (CIK 0000715446) (ANIX) — May 6, 2014
Anixa Biosciences Inc (ANIX) (CIK 0000715446)
Date: May 6, 2014 · CIK: 0000715446 · Accession: 0001513162-14-000288
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-193826
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance CopyTele, Inc. Registration Statement on Form S-3 Filed February 7, 2014, as amended File No. 333-193826
Dear Ms. Woo:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, CopyTele, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m. on Thursday, May 8, 2014, or as soon as thereafter practicable.
Very truly yours,
/s/ Robert A. Berman
Show Raw Text
CORRESP 1 filename1.htm CORRESPONDENCE CopyTele, Inc. 900 Walt Whitman Road Melville, NY 11747 May 6, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jan Woo, Attorney-Adviser Re: CopyTele, Inc. Registration Statement on Form S-3 Filed February 7, 2014, as amended File No. 333-193826 Dear Ms. Woo: Pursuant to Rule 461 under the Securities Act of 1933, as amended, CopyTele, Inc. (the “Company”) hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:00 p.m. on Thursday, May 8, 2014, or as soon as thereafter practicable. Very truly yours, /s/ Robert A. Berman Robert A. Berman President and Chief Executive Officer